Bryostatin 1 - Neurotrope BioScience

Drug Profile

Bryostatin 1 - Neurotrope BioScience

Alternative Names: Bryostatin-1 - Neurotrope

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Blanchette Rockefeller Neurosciences Institute; Neurotrope BioScience
  • Developer Blanchette Rockefeller Neurosciences Institute; Neurotrope BioScience;
  • Class Antineoplastics; Macrocyclic compounds
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Brain injuries; Fragile X syndrome; Niemann-Pick disease type C; Rett syndrome; Stroke

Most Recent Events

  • 20 Jun 2018 Neurotrope initiates a phase II trial in Alzheimer's disease in USA (IV) (NCT03560245)
  • 05 Jan 2018 Neurotrope plans a follow-on confirmatory phase II trial for Alzheimer's disease (an extension trial of NCT02431468)
  • 22 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top